Platelet factor 4 impairs the anticoagulant activity of activated protein C.
AuthorsPreston, Roger J S
Johnson, Jennifer A
Ni Ainle, Fionnuala
Smith, Owen P
Jenkins, P Vince
O'Donnell, James S
AffiliationHaemostasis Research Group, Institute of Molecular Medicine, Trinity College, Dublin, St James' Hospital, Dublin 8, Ireland. email@example.com
Platelet Factor 4/genetics/*metabolism
Protein C/antagonists & inhibitors/*metabolism
MetadataShow full item record
CitationJ Biol Chem. 2009 Feb 27;284(9):5869-75. Epub 2009 Jan 6.
JournalThe Journal of biological chemistry
AbstractPlatelet factor 4 (PF4) is an abundant platelet alpha-granule chemokine released following platelet activation. PF4 interacts with thrombomodulin and the gamma-carboxyglutamic acid (Gla) domain of protein C, thereby enhancing activated protein C (APC) generation by the thrombin-thrombomodulin complex. However, the protein C Gla domain not only mediates protein C activation in vivo, but also plays a critical role in modulating the diverse functional properties of APC once generated. In this study we demonstrate that PF4 significantly inhibits APC anti-coagulant activity. PF4 inhibited both protein S-dependent APC anticoagulant function in plasma and protein S-dependent factor Va (FVa) proteolysis 3- to 5-fold, demonstrating that PF4 impairs protein S cofactor enhancement of APC anticoagulant function. Using recombinant factor Va variants FVa-R506Q/R679Q and FVa-R306Q/R679Q, PF4 was shown to impair APC proteolysis of FVa at position Arg(306) by 3-fold both in the presence and absence of protein S. These data suggest that PF4 contributes to the poorly understood APC resistance phenotype associated with activated platelets. Finally, despite PF4 binding to the APC Gla domain, we show that APC in the presence of PF4 retains its ability to initiate PAR-1-mediated cytoprotective signaling. In summary, we propose that PF4 acts as a critical regulator of APC generation, but also differentially targets APC toward cytoprotective, rather than anticoagulant function at sites of vascular injury with concurrent platelet activation.